A Muti-center, Open-label, Randomized, Phase III Study of Camrelizumab Plus Treatment of Physician Choice Versus Treatment of Physician Choice for Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Systemic Chemotherapy Regimens for Advanced/Metastatic Setting
Latest Information Update: 19 Apr 2024
Price :
$35 *
At a glance
- Drugs Camrelizumab (Primary) ; Eribulin (Primary) ; Gemcitabine (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors Suzhou Suncadia Biopharmaceuticals
- 14 Apr 2024 Status changed from not yet recruiting to discontinued.
- 26 Nov 2021 New trial record